Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience.

[1]  P. Poole‐Wilson,et al.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial , 2004, The Lancet.

[2]  E. Kaplinsky,et al.  The Role of the Critical Event Committee in a Major Cardiovascular Outcome Study , 2002, Blood pressure.

[3]  R. Califf,et al.  Systematic adjudication of myocardial infarction end-points in an international clinical trial , 2001, Current controlled trials in cardiovascular medicine.

[4]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[5]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[6]  S. Lehto,et al.  The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. , 1999, European heart journal.

[7]  P. Poole‐Wilson,et al.  Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-Intestinal Therapeutic System. , 1998, European heart journal.

[8]  T. Hedner,et al.  Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.